KE Awards finalist nomination – Commercialisation Award
Zinc shortlisted for 2023 KE Awards for their collaboration with City, University of London on commercialisation of “Eyecatcher” research
This is in recognition of Zinc’s outstanding partnership with City, University of London on commercialising the ‘Eyecatcher’ research through the commercial vehicle of a spinout, Irida Health. This collaboration represents a groundbreaking model of academia and industry working hand in hand to translate cutting-edge research into real-world impact.
Revolutionising Vision Care: Introducing “Eyecatcher” by Irida Health
After eight years of dedicated research, the academic team led by Dr. Peter Jones at City University, developed ‘The Eyecatcher’, a digital home-monitoring device for glaucoma patients, a solution combining hardware and software for at-home vision field assessments. This innovative technology, comprising smart glasses and an Android phone, empowers patients to conduct vision field assessments at home.
Zinc & City University Collaboration
Navigating the complexities of commercialisation, the ‘Eyecatcher’ team with the support of City University TTO, initially sought licensing avenues with pharmaceutical entities. Challenges arose as the focus remained on in-clinic assessments. Recognising this, the ‘Eyecatcher’ team pivoted towards a spinout model, where the team secured the Healthy Ageing Catalyst Accelerator award, granting six months of intensive support and a dedicated Venture Manager from Zinc.
A pivotal figure in cementing this partnership was Powlami Ghosh, IP and commercialisation consultant at City. From acquiring HEIF funding for prototypes to steering the spinout direction, Ghosh’s expertise was indispensable.
“Thanks to the Zinc Catalyst team for providing the academic team with the necessary resources – be it funding or expert advice on investments/raising finance. I personally would like to see us collaborating more in future.”
Zinc’s Integral Role
Zinc’s contribution was multifaceted. Financially, they injected an initial £60k, followed by £100k from UKRI, facilitating tech development, team establishment, and business model refinement.
With guidance from their Zinc Venture Manager, Baiqu Gonkar, the ‘Eyecatcher’ team maintained momentum, attracting a commercial founding team, and were able to define commercialisation and fundraising strategies. Furthermore, Zinc’s vast network in London and beyond was crucial, connecting the team to invaluable resources, industry experts, external investors, and securing additional funding from the Design Age Institute. Lastly, Zinc supported Irida through equity split and cap table structuring, eventually leading to a successful spinout formation as Irida Health, with ‘Eyecatcher’ as its initial product offering.
“As the Venture Manager at Zinc, working with City has been a testament to how quickly progress happens when academia and industry converge. From the intricacies of the spinout process to the collaborative efforts in integrating an external CEO and COO, our joint partnership has been key to accelerating the pathway for ground breaking research to create real world impact.”
Stephen Hicks, CEO at Irida Health, said:
“As the external CEO stepping into Irida Health, I’ve really appreciated Zinc’s support. Their expertise and network combined with open communication with City University’s TTO, has streamlined the spinout process, and ensured that we have best chance possible for commercial success”
Impact & Collaboration Results
This joint venture between City, University of London, and Zinc has achieved success in multiple dimensions. Notably, the Irida Health spinout stands to create significant societal impact whilst revolutionising the visual field testing at home. This project bolsters the University’s reputation as an innovative powerhouse, while underscoring Zinc’s expertise in commercialising research, and highlighting the potential for more collaborations with research institutions in the future.
For further information, please contact:
Baiqu Gonkar: firstname.lastname@example.org
Zinc is a leading mission-driven venture builder and venture capital firm committed to nurturing and accelerating groundbreaking, research-led startups. With an expert team of founders, academics, IP and commercialisation experts – alongside its network of mentors, investors and partners in the healthcare industry -, Zinc commercialisation programmes provide essential support to transform research into impact.
About City, University of London:
City, University of London is a leading global institution, dedicated to academic excellence, focused on business and the professions, and located in the heart of London. City has a strong tradition of research, and the ‘Eyecatcher’ project exemplifies the University’s commitment to translating academic knowledge into real-world solutions.
Join the Zinc community
Stay up to date with all Zinc updates and future posts as part of our fast growing community.
Impact Report 2023
We started Zinc with the hypothesis that missions are an effective way to attract highly ambitious, talented and experienced groups of innovators, who might not recognise themselves as “classic entrepreneurs” but are ready and able to start a new commercial and successful venture to tackle some of our most pressing societal issues.
The world has overcome the sorts of challenges we face today when it has adopted a mission-based approach to the biggest problems and brought together world-class talent to invent and innovate, e.g: NASA and landing a man on the moon, the LSE blueprinting the British welfare state, or the Gates Foundation aiming to eradicate diseases.
On this basis and assumption, we designed Zinc as a new mission-based Venture Builder — a place where global talent, ‘impact makers’, can join to experiment and develop new solutions to our most pressing societal issues.
To Eliminate Environmental Threats to Our Health
Environmental health threats pose a grave danger to human health and well-being, causing suffering to individuals and communities worldwide. These threats, which include chemical pollution, climate change, and biological hazards, cause acute and chronic diseases and exacerbate existing health conditions.
To protect those we care about, we must tackle the causes of environmental degradation, shield people from the consequences of environmental harm, and, where protection fails, we must mitigate the health impacts they suffer.
This demands action to improve all aspects of our environment: soil, food, air, water, and the built environment. It requires us to focus on every aspect of human health to reduce suffering.
Entrepreneurship and technology are powerful means to tackle these challenges. That’s why we are backing 70 founders to build innovative companies addressing this mission.